All In Biotech

Drug Trial Radar · NCT06625671

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

A Randomized, Double-Blind, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK and PD of DB-2304 for Injection in Healthy Adult Participants and Participants With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Oct 4, 2024

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Conditions

  • Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus

Interventions

  • DB-2304Drug

    DB-2304

  • PlaceboDrug

    Placebo

  • PrednisoneDrug

    Prednisone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TEAEsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  2. SAEsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  3. ECG parametersTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  4. Weight measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  5. Heart Rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  6. Pulse rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  7. Respiratory rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
  8. Body temperature measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • US06-0

    La Palma, California · Recruiting

  • US03-0

    Clearwater, Florida · Recruiting

  • US05-0

    Orlando, Florida · Recruiting

  • US08-0

    Syracuse, New York · Not yet recruiting

  • US04-0

    Irving, Texas · Recruiting

  • US02-0

    San Antonio, Texas · Recruiting

  • Site AUS01-0

    Melbourne, Victoria, Australia · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.